Characteristica | All cases | Adjudicated |
---|---|---|
N | 30 | 27 |
Age, years, median (IQR) | 11 (7-14) | 11 (8-15) |
Gender, no. (%) female | 14 (46.7) | 13 (48.1) |
Race, no. (%) | Â | Â |
   Caucasian | 21 (70.0) | 19 (70.4) |
   African-American | 6 (20.0) | 6 (22.2) |
   Other | 3 (10.0) | 2 (7.4) |
Urban dwelling, no. (%) | 19 (63.3) | 17 (63.0) |
General medical diagnoses, no. (%) | Â | Â |
   Any | 15 (50.0) | 14 (51.9) |
   Cardiovascular | 1 (3.3) | 1 (3.7) |
   Endocrine (non-diabetic, non-DKA) | 0 | 0 |
   Injury | 5 (16.7) | 5 (18.5) |
   Rheumatologic | 2 (6.7) | 1 (3.7) |
   Pregnancy | 1 (3.3) | 1 (3.7) |
Psychiatric diagnoses, no. (%) | Â | Â |
   Mood disorder | 9 (30.0) | 8 (29.6) |
   Anxiety disorder | 3 (10.0) | 3 (11.1) |
   Attention deficit-hyperactivity disorder | 16 (53.3) | 15 (55.6) |
   Externalizing/impulse control disorders | 6 (20.0) | 5 (18.5) |
   Acute stress/adjustment disorders | 5 (16.7) | 3 (11.1) |
Outpatient visits, median no. (IQR)b | 3 (1-10) | 3 (1-10) |
Medications, psychotropic, no. (%) | Â | Â |
   Antipsychotic drug | 6 (20.0) | 6 (22.2) |
   Antidepressant, SSRI or SNRI | 9 (30.0) | 9 (33.3) |
   Antidepressant, tricyclic | 3 (10.0) | 3 (11.1) |
   Antidepressant, other | 1 (3.3) | 1 (3.7) |
   ADHD (stimulants, atomoxetine) | 22 (73.3) | 19 (70.4) |
   Benzodiazepine | 4 (13.3) | 4 (14.8) |
   Mood stabilizer (VPA, CBMZ, LAM) | 2 (6.7) | 2 (7.4) |